Dayvigo is the brand name for lemborexant, a prescription insomnia medication that works differently from older sleep drugs. Employees, job applicants, and hiring managers sometimes ask whether this medication can trigger a positive result on a pre employment or random workplace drug screen. The short answer, based on how lemborexant works and what standard immunoassay panels are built to detect, is that it is not part of any standard drug test panel and there is no published evidence of cross reactivity with the antibody classes those panels use. This article explains why, how screening and confirmation testing actually work, how lemborexant compares to a related sleep drug, and what an employee or employer should do when a prescription sleep medication comes up around a workplace test.
What Dayvigo Is and How It Works
Lemborexant is classified as an orexin receptor antagonist. According to the current prescribing information on DailyMed, Dayvigo blocks the binding of orexin neuropeptides to their receptors, which is believed to suppress wake drive and promote sleep. That mechanism is fundamentally different from the two drug families most people associate with sleep aids. Benzodiazepines (diazepam, lorazepam, temazepam, and similar drugs) and the so called Z drugs such as zolpidem act on GABA receptors. Lemborexant does not. Because the chemical structure and receptor target are different, it does not behave like a benzodiazepine in the body, and it is not metabolized into any compound that benzodiazepine immunoassays are designed to detect.
Lemborexant is also a federally controlled substance. The Drug Enforcement Administration placed lemborexant into Schedule IV, the same schedule that covers most prescription benzodiazepines and Z drugs, based on its abuse potential profile. That scheduling action is documented in the Federal Register final rule placing lemborexant in Schedule IV. Schedule IV status describes legal control and prescribing rules. It does not mean a drug will appear on a workplace drug test, since most employment panels are not built to screen for every Schedule IV compound, only specific drug classes chosen for the testing program.
Why Standard Panels Do Not Flag Lemborexant
A standard workplace urine panel, whether a basic 5 panel or an expanded 10 or 12 panel cup or dip card, is built around antibodies tuned to recognize specific drug classes: amphetamines, cocaine metabolite, opiates, phencyclidine, and THC metabolite on a basic panel, with benzodiazepines, barbiturates, methadone, methamphetamine, oxycodone, or propoxyphene sometimes added on expanded panels. Each antibody reacts to a family of molecules that share a core chemical structure. Lemborexant does not share a structural backbone with any of those drug classes, so there is no documented or published cross reactivity between lemborexant and benzodiazepine, opiate, amphetamine, or any other standard immunoassay antibody. At this time the evidence is limited to the absence of any published cross reactivity finding, not a dedicated clinical cross reactivity study, so this article describes the current state of the evidence rather than claiming the question has been exhaustively studied.
In practice this means a person taking Dayvigo exactly as prescribed should not expect it to cause a presumptive positive on any standard panel class, including the benzodiazepine screen that some people assume covers all sleep medications. Employers and lab staff can review the detailed detection window and cross reactivity information that applies to benzodiazepines specifically in this related overview of the benzodiazepine drug test BZO panel.
Screening Immunoassay vs GC/MS or LC/MS Confirmation
Workplace drug testing almost always happens in two stages. The first stage is an immunoassay screen, the chemistry used in rapid cups, dip cards, and most initial laboratory testing. It is fast and inexpensive, but it reports a presumptive result based on antibody binding, not a specific molecule identification. The second stage, used only when a specimen screens positive, is confirmation by gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS), which identifies the exact compound present. Federal workplace testing programs built on this two step model, including the structure described in the Department of Transportation's testing regulation at 49 CFR Part 40, rely on confirmation to rule out false positives before any result is reported to an employer.
Because lemborexant is not a target of any standard screening antibody, a specimen from someone taking Dayvigo should not screen positive for benzodiazepines, opiates, or any other standard class in the first place, which means it would not advance to confirmation testing either. A laboratory could, in theory, run a dedicated assay that specifically targets lemborexant, but that is not part of routine employment drug testing menus and would only occur if a program ordered it by name for a specific clinical or forensic reason.
Dayvigo Compared to Suvorexant (Belsomra)
Lemborexant is not the only orexin receptor antagonist on the market. Suvorexant, sold under the brand name Belsomra, works through the same receptor mechanism and carries the same Schedule IV status. The table below compares the two for workplace testing purposes. A full breakdown of suvorexant specifically is available in this related post on whether Belsomra shows up on a drug test.
| Feature | Dayvigo (lemborexant) | Belsomra (suvorexant) |
|---|---|---|
| Drug class | Orexin receptor antagonist | Orexin receptor antagonist |
| DEA schedule | Schedule IV | Schedule IV |
| Benzodiazepine (GABA site) activity | No | No |
| Standard 5 panel coverage | Not included | Not included |
| Standard expanded panel (benzodiazepine, barbiturate) coverage | Not included, no documented cross reactivity | Not included, no documented cross reactivity |
| FDA label impairment warning | Next day drowsiness and driving impairment | Next day drowsiness and driving impairment |
Next Day Impairment and Safety Sensitive Work
The prescribing information for Dayvigo carries a warning about next day impairment, including reduced alertness and a specific caution against driving or operating machinery until a person knows how the medication affects them, consistent with the labeling reviewed on DailyMed. This matters for employers with safety sensitive positions, such as commercial driving, machine operation, or aviation and rail roles covered by federal testing rules, even though the medication will not appear on a drug test result. A drug test measures the presence of specific substances. It does not measure fitness for duty or observable impairment on a given shift. Supervisors who notice signs of impairment, regardless of the cause, generally have the option to use a reasonable suspicion evaluation and a fitness for duty process rather than relying on a drug test to catch a sedating prescription medication that standard panels are not designed to detect.
Prescription Documentation and the Medical Review Officer Process
Even though lemborexant itself is not expected to trigger a positive screen, any employee undergoing a regulated drug test who takes a prescription controlled substance should keep that prescription documentation available and disclose it if a medical review officer (MRO) contacts them about a different result. The MRO review process, including how a certified MRO verifies legitimate medical explanations for a laboratory confirmed positive result, is set out in 49 CFR Part 40, Subpart G. This process exists specifically so that a legitimate prescription is not treated the same as unauthorized drug use, and it applies to the substances that are actually included on the panel being used, not to every medication an employee happens to take. Employers building or reviewing a workplace testing program can find general program background through the Substance Abuse and Mental Health Services Administration's workplace resources.
What This Means for Employers and Employees
For an employer, the practical point is that a standard panel, whether a 5 panel urine cup, a 10 panel dip card, or an oral fluid test, is not a tool for identifying who is taking a sedating sleep medication like Dayvigo. Panel selection should be based on the drug classes the program actually needs to screen for, and any concern about on the job impairment from a sedating prescription medication should generally be handled through a fitness for duty or reasonable suspicion policy rather than an expectation that the drug test itself will catch it. Employers sourcing cups, dip cards, or oral fluid devices for a documented panel can review current options through the drug test cup collection.
For an employee, the practical point is that a legitimate Dayvigo prescription should not, based on the current evidence, cause a false positive on a standard panel, and there is no documented cross reactivity to be concerned about. If a different result comes back positive for an unrelated reason, the prescription and pharmacy documentation should be ready to present to the MRO as part of the verification process described above.
Frequently asked questions
Will Dayvigo cause a positive drug test?
Dayvigo (lemborexant) is not included in standard 5 panel or expanded panel immunoassay testing, and there is no published cross reactivity between lemborexant and the benzodiazepine, opiate, amphetamine, or other antibody classes those panels use, so it should not cause a positive result on a standard workplace drug test.
Is lemborexant a benzodiazepine?
No. Lemborexant is an orexin receptor antagonist. Benzodiazepines act on GABA receptors, a different mechanism entirely, and lemborexant does not produce the metabolites that benzodiazepine immunoassays are designed to detect.
Does Dayvigo show up on a 10 panel drug test?
A standard 10 panel drug test screens for specific drug classes such as amphetamines, opiates, benzodiazepines, and THC. Lemborexant is not one of the compounds those antibodies target, so it is not expected to appear on a 10 panel result.
Can an employer test specifically for Dayvigo?
Routine employment drug testing menus do not include a dedicated lemborexant assay. A laboratory could run a specific test for it only if a program ordered that analyte by name, which is not part of standard workplace panels.
Does Dayvigo cause impairment that matters for safety sensitive jobs?
The official label for Dayvigo warns of possible next day drowsiness and impaired alertness, including a caution about driving. That is a fitness for duty consideration, generally addressed through reasonable suspicion or fitness for duty procedures, separate from whether the drug itself shows up on a test.
What should an employee prescribed Dayvigo for a safety sensitive or DOT covered job do?
Keep the prescription and pharmacy documentation on hand, disclose it to a medical review officer if asked about any drug test result, and discuss any concerns about daytime drowsiness with the prescribing clinician, since the MRO process exists to verify legitimate prescriptions for substances that actually appear on a test result.
This article is general information for employers and employees about how drug test panels and medication detection work. It is not legal or medical advice. Employers should consult qualified counsel and a certified medical review officer for specific testing program and compliance decisions.
